Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study.

"Declarations Ethics approval and consent to participateThis study was conducted in accordance with the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, International Conference on Harmonisation guidelines for Good Clinical Practice, and applicable local laws and regulations. Patients provided written informed consent before undergoing any study procedures. The appropriate institutional review board for each participating site approved the study protocol, patient consent form and other relevant documents. Consent for publicationNot applicable. Competing interestsLS, HL and CQ are full-time employees of Eli Lily and Company. SY serves as associated editor of the Journal of Headache and Pain and as a member of the International Headache Society. MZ has no competing interests. JZ, LZ, DC, KS, GL, XY and SY declare receiving clinical research fees from Eli Lilly and Company for participating as investigators in the PERSIST study. Competing interests LS, HL and CQ are full-time employees of Eli Lily and Company. SY serves as associated editor of the Journal of Headache and Pain and as a member of the International Headache Society. MZ has no competing interests. JZ, LZ, DC, KS, GL, XY and SY declare receiving clinical research fees from Eli Lilly and Company for participating as investigators in the PERSIST study."

"Funding The PERSIST study was funded by Eli Lilly and Company."

"Trial registration ClinicalTrisABSTRACT_pals.gov NCT03963232, registered May 24, 2019."